Pharmicell (005690) Fundamentals 2026 — P/E 14.8x, Revenue Analysis | SniperIQ
Pharmicell (005690) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩643.2B, trading at ₩10720.00 on the KSC. This SniperIQ fundamentals page covers Pharmicell's valuation (P/E 14.8x, P/B 4.8x), profitability (net margin 35.2%), revenue (₩114.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Pharmicell's market cap?
Pharmicell (005690) has a market capitalization of approximately ₩643.2B, trading at ₩10720.00 on the KSC. Market cap moves with the live share price.
What is Pharmicell's P/E ratio?
Pharmicell's trailing twelve-month P/E ratio is 14.8x, with a price-to-book (P/B) of 4.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Pharmicell?
Pharmicell runs a net profit margin of 35.2%, a gross margin of 44.6%, and an operating margin of 31.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Pharmicell generate?
Pharmicell reported revenue of ₩114.1B for fiscal year 2025, with net income of ₩40.3B and earnings per share (EPS) of 671.97. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Pharmicell pay a dividend?
Pharmicell offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Pharmicell financially healthy?
Pharmicell carries a debt-to-equity ratio of 0.15x and a current ratio of 6.86x, with a market beta of 0.59. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Pharmicell a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pharmicell (005690) the key facts are: market cap ₩643.2B, P/E 14.8x, revenue ₩114.1B, 52-week range 10160-21150. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Pharmicell's full fundamentals live
Get Pharmicell's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.